IL6 and metabolic syndrome: Consistent with previous studies (5, 16), a positive relationship between lactosylceramides with IL-6, CRP, fibrinogen, and sICAM was found in subjects with MetS, strongly suggesting that high levels of these β-glycosphingolipids may be associated with increased risk of future cardiovascular events.